Rockley Photonics Names Richard Kuntz, M.D., to Board of Directors
09 August 2022 - 6:15AM
Business Wire
Rockley Photonics (NYSE: RKLY), a global leader in
photonics-based health monitoring and communications solutions,
today announced that it named Richard Kuntz, M.D., M.Sc., to its
board of directors. Dr. Kuntz will join the board as an independent
director, effective August 8, 2022.
“We are delighted to welcome Richard Kuntz to our board of
directors. A proven leader in healthcare, Rick brings a blend of
world-class industry, clinical, and research experience that makes
him uniquely qualified to serve on our board,” said Dr. Andrew
Rickman, chairman and chief executive officer of Rockley Photonics.
“His broad background spans multiple aspects of healthcare, from
leading Medtronic’s neuromodulation business and subsequently
serving as Medtronic’s global chief medical and scientific officer
to serving as an associate professor of medicine at Harvard Medical
School. Having applied our board skills matrix to assess our
existing competencies, we determined that Rick’s academic and
industry experience will complement the competencies of our
board.”
Prior to his 17 years at Medtronic, Dr. Kuntz was the founder
and chief scientific officer of the Harvard Clinical Research
Institute, a university-based contract research organization which
coordinates National Institutes of Health (NIH) and industry
clinical trials with the U.S. Food and Drug Administration.
Additionally, he directed numerous multicenter clinical trials and
authored more than 250 original peer-reviewed publications.
Additionally, Dr. Kuntz served as an associate professor of
medicine at Harvard Medical School, chief of the division of
clinical biometrics, and as an interventional cardiologist in the
division of cardiovascular diseases at the Brigham and Women’s
Hospital in Boston. He also has served as a member of the board of
governors of the Patient Centered Outcomes Research Institute
(PCORI), part of the Affordable Care Act, from 2010-2018.
Dr. Kuntz also served as an advisor to multiple national and
regional committees, including the National Academy of Medicine
(NAM): Leadership Consortium for a Value & Science-Driven
Health System, and co-chair of the NAM Evidence Mobilization Action
Committee; the NIH: National Center for Advancing Translational
Science, and the NIH: Cures Acceleration Network. He is presently
serving as a working group member of NIH: Helping to End Addiction
Long-term® (HEAL) program.
Dr. Kuntz graduated from Miami University and received his
medical degree from Case Western Reserve University School of
Medicine. He completed his residency and chief residency in
internal medicine at the University of Texas Southwestern Medical
School, Parkland Hospital, Dallas, and then completed fellowships
in cardiovascular diseases and interventional cardiology at the
Beth Israel Hospital and Harvard Medical School, Boston. Dr. Kuntz
received his Master of Science in biostatistics from the Harvard
T.H. Chan School of Public Health.
Dr. Kuntz’s appointment expands Rockley’s board to nine
members.
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220808005266/en/
Media Debra Raine RaineMakers Telephone: +1 415-349-7432 Email:
rockley-pr@rainemakers.com Investors Gwyn Lauber Rockley Photonics
Telephone: +1 626-995-0001 Email:
investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Jan 2025 to Feb 2025
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Feb 2024 to Feb 2025